PART I Item 1. Bus iness. Overview We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact indu...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001193125-26-124143 | EDGAR | 87K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-045726 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0000950170-24-035919 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009492 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0000950170-22-004407 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001564590-21-015103 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001564590-20-013207 | EDGAR | — |
| 2019-03-27 | 2018-12-31 | 0001564590-19-009580 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280202 | EDGAR | 65K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108834 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071389 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126322 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093949 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056960 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061108 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040583 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021236 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025052 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017399 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009669 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001193125-26-124107 | EDGAR | 2K words |
| 2026-03-13 | 0001193125-26-105083 | EDGAR | — |
| 2025-11-13 | 0001193125-25-280173 | EDGAR | — |
| 2025-10-06 | 0001193125-25-231860 | EDGAR | — |
| 2025-09-19 | 0001193125-25-209068 | EDGAR | — |
| 2025-09-04 | 0000950170-25-113023 | EDGAR | — |
| 2025-08-11 | 0001193125-25-177510 | EDGAR | — |
| 2025-08-04 | 0001193125-25-172207 | EDGAR | — |
| 2025-06-13 | 0000950170-25-086155 | EDGAR | — |
| 2025-05-22 | 0001193125-25-125153 | EDGAR | — |
158 total filings indexed. 128 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001746466 |
| Ticker | EQ |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.equilliumbio.com |
| Listed | 2018-10-12 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/EQ (~200 tokens, structured JSON with cryptographic provenance)